Get the Stockscreener App
43.75
0.73%
-0.32
After Hours:
43.75
Kymera Therapeutics Inc stock is traded at $43.75, with a volume of 415.04K.
It is down -0.73% in the last 24 hours and up +0.25% over the past month.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
See More
Previous Close:
$44.07
Open:
$43.33
24h Volume:
415.04K
Relative Volume:
0.49
Market Cap:
$2.85B
Revenue:
$58.89M
Net Income/Loss:
$-240.88M
P/E Ratio:
-14.11
EPS:
-3.1
Net Cash Flow:
$-239.96M
1W Performance:
-4.58%
1M Performance:
+0.25%
6M Performance:
+10.51%
1Y Performance:
-5.30%
1-Day Range:
$43.24
$44.14
1-Week Range:
$43.21
$46.48
52-Week Range:
$19.45
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Name
Kymera Therapeutics Inc
Sector
Industry
Phone
857-285-5314
Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
43.75 | 3.09B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jun-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-02-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-20-25 | Resumed | Stifel | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-26-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-22-24 | Initiated | Oppenheimer | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Jan-04-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-30-23 | Initiated | Truist | Buy |
| May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-06-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-08-22 | Initiated | Raymond James | Mkt Perform |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Aug-03-22 | Initiated | Goldman | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | JP Morgan | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Sep-30-21 | Initiated | B. Riley Securities | Neutral |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Sep-15-20 | Initiated | BofA Securities | Neutral |
| Sep-15-20 | Initiated | Cowen | Outperform |
| Sep-15-20 | Initiated | Guggenheim | Buy |
| Sep-15-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Kymera Therapeutics Inc Stock (KYMR) Latest News
What is Kymera Therapeutics Inc. company’s growth strategyEarnings Report Entry Points For Fast Growth - jammulinksnews.com
Why is Kymera Therapeutics Inc. stock attracting strong analyst attentionEarnings Report Insights To Watch Now - jammulinksnews.com
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer - MSN
Kymera Therapeutics Inc. Chart Enters High Volatility ZoneSecure Return Focused Investment Plan Released - metal.it
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
Published on: 2025-07-29 17:18:26 - metal.it
How did KYMR's Q1 2025 EPS forecast compare to past trends? - AInvest
What analysts say about Kymera Therapeutics Inc. stock outlookMarket Surge Signal for Swing Traders Triggered - metal.it
Is Kymera Therapeutics Inc. a growth stock or a value stockAchieve breakthrough profits with expert advice - jammulinksnews.com
What are Kymera Therapeutics Inc. company’s key revenue driversFast-track wealth growth - jammulinksnews.com
How volatile is Kymera Therapeutics Inc. stock compared to the marketAchieve breakthrough results with expert guidance - jammulinksnews.com
How many analysts rate Kymera Therapeutics Inc. as a “Buy”Achieve breakthrough investment performance - jammulinksnews.com
Does Kymera Therapeutics Inc. stock perform well during market downturnsUnlock your trading potential today - jammulinksnews.com
What makes Kymera Therapeutics Inc. stock price move sharply200 Percent Gain Alert - metal.it
Kymera Therapeutics Inc. Stock Analysis and ForecastSuperior returns - PrintWeekIndia
Will Kymera Therapeutics Inc. stock benefit from AI tech trendsOutstanding trading profits - jammulinksnews.com
What drives Kymera Therapeutics Inc. stock priceOutstanding growth strategies - PrintWeekIndia
Is Kymera Therapeutics Inc. a good long term investmentFree Stock Market Query - Autocar Professional
What analysts say about Kymera Therapeutics Inc. stockHigh-profit stock alerts - jammulinksnews.com
Kymera Therapeutics Inc Stock (KYMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):